| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DEXI |
| Uniprot No | O95424 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-95aa |
| 氨基酸序列 | MLGARVAAHLDALGPLVPYVPPPLLPSMFYVGLFFVNVLILYYAFLMEYIVLNVGLVFLPEDMDQALVDLGVLSDPGSGLYDADSELDVFDAYLE |
| 预测分子量 | 10,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DEXI重组蛋白的模拟参考文献示例(注：内容为虚构，仅供参考)：
---
1. **文献名称**：*DEXI重组蛋白的分子特性及其在DNA修复中的功能研究*
**作者**：Lee S, et al.
**摘要**：本研究解析了DEXI重组蛋白的结构，证实其作为核酸外切酶参与DNA损伤修复的分子机制，为癌症治疗中的基因组稳定性研究提供新思路。
2. **文献名称**：*重组DEXI蛋白在抗病毒先天免疫中的调控作用*
**作者**：Chen R, et al.
**摘要**：通过体外实验发现，DEXI重组蛋白能够增强宿主细胞对RNA病毒的识别能力，并通过激活干扰素信号通路抑制病毒增殖，提示其潜在的免疫调节应用价值。
3. **文献名称**：*高效表达与纯化DEXI重组蛋白的工艺优化*
**作者**：Gupta A, et al.
**摘要**：开发了一种基于哺乳动物细胞表达系统的DEXI重组蛋白规模化生产方案，优化后的纯化工艺显著提高蛋白得率与活性，支持后续功能研究。
4. **文献名称**：*DEXI重组蛋白在类风湿性关节炎模型中的治疗潜力*
**作者**：Martinez P, et al.
**摘要**：动物实验表明，外源性DEXI重组蛋白可减轻炎症反应并抑制关节损伤，提示其在自身免疫性疾病治疗中的应用前景。
---
**注意**：以上文献为示例性内容，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实发表的论文。
DEXI (Dextranase I) recombinant protein is a genetically engineered enzyme derived from microbial sources, primarily studied for its ability to hydrolyze dextran—a complex polysaccharide composed of α-1.6-linked glucose units with occasional α-1.3 branches. Dextran is commonly produced by lactic acid bacteria, such as *Leuconostoc* and *Streptococcus* species, and its accumulation can cause industrial challenges (e.g., clogging in sugar processing) or medical issues (e.g., dental plaque formation). Naturally occurring dextranases are rare and often exhibit suboptimal activity under industrial conditions, prompting the development of recombinant variants like DEXI.
The recombinant DEXI protein is typically produced by cloning the *dexi* gene into expression systems like *E. coli* or yeast, enabling scalable production with high purity. Structural studies reveal that DEXI belongs to glycoside hydrolase family 49 (GH49), characterized by a conserved (β/α)₈ TIM barrel fold and a calcium-binding site critical for catalytic stability. Its engineered variants often feature mutations to enhance thermostability, pH tolerance, or substrate specificity, making them suitable for diverse applications. For instance, in the food industry, DEXI is used to break down dextran in sugar syrups, improving refining efficiency. In healthcare, it shows potential in dental care products to prevent biofilm formation or in therapeutic strategies targeting dextran-producing pathogens. Recent research also explores its utility in biotechnology, such as synthesizing oligosaccharides or functionalizing biomaterials. Despite its niche applications, DEXI's commercialization remains limited, with ongoing studies focused on optimizing enzymatic properties and cost-effective production methods to expand its industrial relevance.
×
